Metastatic melanoma: prognostic factors and survival in patients with brain metastases.

摘要: Brain metastases from malignant melanoma carry a poor prognosis. Novel systemic agents have improved overall survival (OS), but the value of whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) remains uncertain. The melanoma-specific graded prognostic assessment (msGPA) provides useful information, relevance to modern-day population has not been validated. Since 2011, 53 patients received treatment for brain at Rosemere Cancer Centre medical oncology clinic. Data were collated on demographic factors survival. Survival analyses performed using Kaplan–Meier methods. Cox regression was used identify univariate multivariate analysis. OS date diagnosis 4.83 months (range 0.27–30.4 months). On analysis, BRAF, performance status msGPA significant indicators (p = 0.0056, p = 0.0039 p = 0.0001 respectively). remained analysis (p = 0.0006). BRAF-positive receiving targeted (n = 22) significantly better than BRAF-negative (n = 26), with median times 8.2 3.7 months respectively (p = 0.0039, HR 2.36). SRS combined (n = 16) produced an 13.5 months. Patients WBRT alone (n = 21) had prognosis (2.2 months). valid indicator in era novel treatments melanoma. during their favorable outcomes. should be use caution active management metastases.